top of page
OraLiva_edited_edited.jpg

The Future of Cancer Diagnostics

Oraliva provides noninvasive, painless, reliable, clinically validated AI linked diagnostics for the detection of oral cancer and oral dysplasia. A point of care/near patient testing platform technology for a broad range of cancers.

OraLiva has developed a next generation programmable single cell cytology platform that is suitable for early cancer detection.

This agile platform allows for rapid expansion to a large menu of tests. In collaboration with the McDevitt Laboratory at NYU, large clinical studies have been completed to define signatures of early disease. OraLiva’s first application is targeted for Q3 2023 in the area of oral cancer.

OraLiva_Torso-01-01.jpg
image (13).png

OraLiva saves lives and costs through early oral cancer detection.

Oral cancer is one of the most expensive cancers and one with the poorest outcomes.

C-AIIDE:
Cytology
Artificial
Intelligence
IDEntification

OraLiva’s C-AIIDE is the first portable, programmable cytology platform for use at point of care.

OraLiva.75PS.jpg
bottom of page